What's Behind Stryker's Solid Q3 Results

Stryker (NYSE: SYK) ranks as one of the biggest winners among blue-chip stocks so far in 2019. The medical device giant's shares have soared nearly 35% year to date.

That strong performance was put to the test when Stryker announced its third-quarter results after the market closed on Tuesday. However, Stryker didn't strike out. Here are the highlights from the company's Q3 update.

Physician showing a patient a human spine model

Image source: Getty Images.

By the numbers

Stryker reported revenue of $3.58 billion in the third quarter, up 10.6% year over year. This result matched the consensus Wall Street Q3 revenue estimate.

The company announced net income in the third quarter of $466 million, or $1.23 per share, based on generally accepted accounting principles (GAAP). This reflected significant deterioration from the GAAP net income of $590 million, or $1.55 per share, posted in the prior-year period.

Stryker reported adjusted net income of $1.91 per share, compared with $1.69 per share in the same period in 2018. This narrowly beat the average analysts' Q3 earnings estimate of $1.90 per share.

Behind the numbers

Sales in all of Stryker's business segments rose in the third quarter. Orthopedic sales increased by nearly 8% to $1.3 billion. Medical-surgical sales rose 9% to $1.6 billion. Neurotechnology and spine segment sales jumped 19% to $700 million. 

Foreign exchange fluctuations weighed on Stryker's Q3 revenue to some extent. On a constant-currency basis, the company's revenue increased by 11.5% over the prior-year period.

The company's bottom line, however, went in the wrong direction -- at least on a GAAP basis. What happened? Stryker's tax bill was a lot worse than a year ago. In the third quarter of 2018, the company enjoyed a $56 million tax benefit. Stryker paid $115 million in income taxes in the recent quarter. That swing caused the steep year-over-year decline in earnings.

Stryker's adjusted earnings per share (EPS) figure for Q3 factored out the impact of these taxes. On a more apples-to-apples basis, the company's bottom line improved nicely over the same quarter last year.

Looking ahead

CEO Kevin Lobo liked what he saw with Stryker's growth in Q3. He said the company expects "this momentum to continue, which positions us well to deliver above the high end of our initial guidance range for both organic sales and adjusted EPS."

Stryker's revised guidance backs up Lobo's optimism. The company now anticipates full-year adjusted net earnings per share to be between $8.20 and $8.25, compared with its prior guidance of $8.15 to $8.25. For the fourth quarter of 2019, Stryker expects adjusted net earnings per share to fall between $2.43 and $2.48.

Investors can also look forward to an impact from Stryker's acquisition of Mobius Imaging and its sister company, GYS Tech. Stryker announced the closing of this transaction on Oct. 21.

10 stocks we like better than Stryker
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Stryker wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 1, 2019


Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.